In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

A disruption in federal funds has jeopardized HIV testing and outreach in the U.S. South, and researchers warn of a ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

Without an extra boost of support to get tested or stay on treatment, many people living with HIV will grow sicker and stand ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...